Grade of deceased donor liver macrovesicular steatosis impacts graft and recipient outcomes more than the Donor Risk Index

Journal of Gastroenterology and Hepatology (Australia)

Volumn 27, Issue 3, 2012, Pages 540-546

  de Graaf, Esther L ^a   Kench, James ^b   Dilworth, Pamela ^b   Shackel, Nicholas A ^b   Strasser, Simone I ^b   Joseph, David ^b   Pleass, Henry ^b   Crawford, Michael ^b   Mccaughan, Geoff W ^b   Verran, Deborah J ^b  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Allograft; Donor Risk Index; Steatosis; Transplantation

Indexed keywords

ADULT; ARTICLE; BODY MASS; DISEASE SEVERITY; DONOR RISK INDEX; FATTY LIVER; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; LIVER BIOPSY; LIVER MACROVESICULAR STEATOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETRANSPLANTATION;

EID: 84857329752     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2011.06844.x     Document Type: Article

References (25)

1. Durand F, Renz JF, Alkofer B etal. Report of the Paris consensus meeting on expanded criteria donors in liver transplantation. Liver Transpl. 2008; 14: 1694-707.
2. Attia M, Silva MA, Mirza DF. The marginal liver donor-an update. Transpl. Int. 2008; 21: 713-24.
3. Verran D, Kusyk T, Painter D etal. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl. 2003; 9: 500-5.
4. Briceno J, Padillo J, Rufian S, Solrzano G, Pera C. Assignment of steatotic livers by the mayo model for end-stage liver disease. Transpl. Int. 2005; 18: 577-83.
5. Zamboni F, Franchetto A, David E etal. Effect of macrovesicular steatosis and other donor and recipient characteristics on the outcome of liver transplantation. Clin. Transpl. 2001; 15: 53-7.
6. Yoong KF, Gunson BK, Neil DA etal. Impact of donor liver microvesicular steatosis on the outcome of liver transplantation. Transplant. Proc. 1999; 31: 550-1.
7. Fishbein TM, Fiel MI, Emre S etal. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997; 64: 248-51.
8. McCormack L, Petrowsky H, Jochum W, Mulhaupt B, Weber M, Clavien P-A. Use of severely steatotic grafts in liver transplantation. A matched case control study. Ann. Surg. 2007; 246: 940-8.
9. Noujaim HM, de Ville de Goyet J, Montero EF etal. Expanding postmortem donor pool using steatotic liver grafts: a new look. Transplantation 2009; 87: 919-23.
10. Feng S, Goodrich NP, Bragg-Gresham JL etal. Characteristics associated with liver allograft failure: the concept of a donor risk index. Am. J. Transplant. 2006; 6: 783-90.
11. Spitzer A, Lao OB, Dick AAS etal. The biopsied donor liver: incorporating macrosteatosis into high-risk donor assessment. Liver Transpl. 2010; 16: 874-84.
12. Angele M, Rentsch M, Hartl W etal. Effect of graft steatosis on liver function and organ survival after liver transplantation. Am. J. Surg. 2008; 195: 214-20.
13. Burra P, Loreno M, Russo F etal. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl. 2009; 15: 619-28.
14. Foo H, Molmenti E, Thuluvath P. The effect of donor body mass index on primary graft nonfunction, retransplantation rate and early graft and patient survival after liver transplantation. Liver Transpl. 2003; 9: 72-8.
15. Bonney G, Aldersley M, Asthana S etal. Donor risk index and meld interactions in predicting long-term graft survival: a single-centre experience. Transplantation 2009; 87: 1858-63.
16. Maluf D, Edwards E, Kauffman H. Utilization of extended donor criteria liver allograft: is the elevated risk of failure independent of the model for end-stage liver disease score of the recipient? Transplantation 2006; 82: 1653-7.
17. Tekin K, Imber C, Atli M etal. A simple scoring system to evaluate the effects of cold ischemia on marginal donor liver donors. Transplantation 2004; 77: 411-6.
18. Tector A, Mangus R, Chestovich P etal. Use of extended criteria livers decreases wait time for liver transplantation without adversely impacting post transplant survival. Ann. Surg. 2006; 244: 439-50.
19. Marsman W, Wiesner R, Rodriguez L etal. Use of fatty donor liver is associated with diminished early patient and graft survival. Transplantation 1996; 62: 1246-51.
20. Baccarini U, Adani G, Lorenzin D, Donini A, Risaliti A. The role of steatosis of the liver graft in the development of post-transplant biliary complications. Transpl. Int. 2010; 23: 239.
21. Lo I, Lefkowitch J, Feirt N etal. Utility of liver allograft biopsy obtained at procurement. Liver Transpl. 2008; 14: 639-46.
22. Fiorentino M, Vasuir F, Ravaioli M etal. Predictive value of frozen-section analysis in the histological assessment of steatosis before liver transplantation. Liver Transpl. 2009; 15: 1821-5.
23. Rey J, Wirges U, Dienes H, Fries J. Hepatic steatosis in organ donors: disparity between surgery and histology. Transplant. Proc. 2009; 41: 2557-60.
24. Fiorini R, Kirtz J, Periyasamy B etal. Development of an unbiased method for the estimation of liver steatosis. Clin. Transpl. 2004; 18: 700-6.
25. El-Badry A, Breitenstein S, Jochum W etal. Assessment of hepatic steatosis by expert pathologists. The end of a gold standard. Ann. Surg. 2009; 250: 691-7.